Kolexia
Pivot Xavier Oncologie médicale
Pivot Xavier
Oncologie médicale
Centre Paul Strauss
Strasbourg, France
406 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Récidive tumorale locale Tumeurs du sein triple-négatives Carcinomes Tumeurs colorectales Tumeurs de la prostate Fatigue Tumeurs du poumon

Collaborateurs

Voir plus
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Eisinger Francois
Eisinger Francois
Centre Paoli-Calmettes, Marseille, France
Curtit Elsa
Curtit Elsa
Hôpital Jean-Minjoz, Besançon, France
Morere Jean François
Morere Jean François
Hôpital Paul Brousse, Villejuif, France

Industries

Voir plus
Lilly
2 collaboration(s)
Dernière en 2021
Boehringer Ingelheim
2 collaboration(s)
Dernière en 2020
Novartis
1 collaboration(s)
Dernière en 2020
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Essai Clinique (Lilly)   11 mars 2024
Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization.
Advanced healthcare materials   05 mars 2024
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE): A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
Essai Clinique (Roche)   29 février 2024
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC: A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
Essai Clinique (Samsung Bioepis Co., Ltd.)   31 janvier 2024
A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients.
Journal of cachexia, sarcopenia and muscle   06 janvier 2024
Subcutaneous Administration of a Zwitterionic Chitosan-Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal Antibodies.
Advanced materials (Deerfield Beach, Fla.)   17 décembre 2023
Influence of pneumatic transportation on the stability of monoclonal antibodies.
Scientific reports   10 décembre 2023
100 ans d'innovations et de découvertes en cancérologie_BFM_Alsace Pr Pivot
Youtube @ ICANS - Institut de cancérologie Strasbourg Europe   20 novembre 2023
MONALEESA-3: A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment
Essai Clinique (Novartis)   02 novembre 2023
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
JAMA oncology   10 août 2023